Suppr超能文献

测量神经纤维瘤病 1 型皮肤神经纤维瘤对生活质量的影响。

Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.

机构信息

From the Department of Dermatology (S.M., M.D.), Biostatistics Core, Masonic Cancer Center (N.R.), and Department of Pediatrics (C.M.), University of Minnesota, Minneapolis; Department of Clinical Genetics (Y.B., C.W.), Royal North Shore Hospital; Faculty of Medicine (Y.B.), University of Sydney, Australia; and Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston.

出版信息

Neurology. 2021 Aug 17;97(7 Suppl 1):S25-S31. doi: 10.1212/WNL.0000000000012427. Epub 2021 Jul 6.

Abstract

OBJECTIVE

In order to explore the use of Skindex scoring in patients with neurofibromatosis type 1 (NF1) across multiple clinical sites and inform design of additional quality of life measures, we analyzed correlations between Skindex, site, and clinical measures for 79 patients with NF1 from specialized clinics in Sydney, Australia (Royal North Shore Hospital [RNS]) and Minneapolis, Minnesota (University of Minnesota [UMN]).

METHODS

The relationship between clinical factors and Skindex scores were explored by clinic site and overall.

RESULTS

A total of 40 participants were recruited from RNS and 39 from UMN. Female sex, total number of cutaneous neurofibroma (cNF), and whether cNF were present on the face correlated highly with Skindex and not Riccardi scores. The UMN site had lower average scores, but these differences were almost entirely removed after adjusting for age, sex, facial cNF, and total cNF number.

CONCLUSIONS

The development of cNF in adolescence and adulthood in NF1 often leads to progressive disfigurement and discomfort and is among one of the most common reasons for patients to seek medical treatment. Skindex has been used to assess skin-related quality of life in NF1 previously but is not specific to NF1. These findings highlight the need for a low threshold for referral to dermatologists for all patients with NF1 regardless of the severity of disease. The finding that facial cNF and higher total number of cNF correlates with poorer skin-related quality of life may benefit design of more specific NF1 skin-related quality of life measures.

摘要

目的

为了探索 Skindex 评分在 1 型神经纤维瘤病(NF1)患者中的应用,在多个临床场所进行研究,并为其他生活质量测量方法的设计提供信息,我们分析了来自澳大利亚悉尼皇家北岸医院(RNS)和明尼苏达州明尼阿波利斯大学(UMN)专门诊所的 79 例 NF1 患者的 Skindex、临床和临床指标之间的相关性。

方法

通过临床场所和整体来探索临床因素与 Skindex 评分之间的关系。

结果

共招募了来自 RNS 的 40 名参与者和来自 UMN 的 39 名参与者。女性性别、皮肤神经纤维瘤(cNF)总数以及 cNF 是否存在于面部与 Skindex 和 Riccardi 评分高度相关。UMN 场所的平均评分较低,但在调整年龄、性别、面部 cNF 和总 cNF 数量后,这些差异几乎完全消除。

结论

NF1 患者在青春期和成年期 cNF 的生长通常会导致容貌受损和不适,这是患者寻求治疗的最常见原因之一。Skindex 之前曾用于评估 NF1 患者的皮肤相关生活质量,但并不专门针对 NF1。这些发现强调了所有 NF1 患者都应及时转诊给皮肤科医生的必要性,无论疾病严重程度如何。面部 cNF 和更高的 cNF 总数与较差的皮肤相关生活质量相关的发现可能有助于设计更具体的 NF1 皮肤相关生活质量测量方法。

相似文献

1
Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Neurology. 2021 Aug 17;97(7 Suppl 1):S25-S31. doi: 10.1212/WNL.0000000000012427. Epub 2021 Jul 6.
2
The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1.
J Dermatol. 2024 Aug;51(8):1050-1059. doi: 10.1111/1346-8138.17276. Epub 2024 Jun 24.
3
Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1.
JAMA Dermatol. 2024 Oct 1;160(10):1091-1098. doi: 10.1001/jamadermatol.2024.2912.
5
Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1359-1366. doi: 10.1111/jdv.18140. Epub 2022 Apr 28.
6
Cutaneous neurofibromas: Current clinical and pathologic issues.
Neurology. 2018 Jul 10;91(2 Suppl 1):S5-S13. doi: 10.1212/WNL.0000000000005792.
7
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Neurology. 2021 Aug 17;97(7 Suppl 1):S15-S24. doi: 10.1212/WNL.0000000000012425. Epub 2021 Jul 6.
8
Creating a comprehensive research strategy for cutaneous neurofibromas.
Neurology. 2018 Jul 10;91(2 Suppl 1):S1-S4. doi: 10.1212/WNL.0000000000005789.
9
Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
JCI Insight. 2019 Apr 30;5(11):128881. doi: 10.1172/jci.insight.128881.

引用本文的文献

3
The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1.
J Dermatol. 2024 Aug;51(8):1050-1059. doi: 10.1111/1346-8138.17276. Epub 2024 Jun 24.
5
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sci Adv. 2024 May 3;10(18):eadk4946. doi: 10.1126/sciadv.adk4946. Epub 2024 May 1.
6
Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1.
Orphanet J Rare Dis. 2024 Feb 24;19(1):85. doi: 10.1186/s13023-024-03078-0.
7
Global research trends in cutaneous neurofibromas: A bibliometric analysis from 2003 to 2022.
Skin Res Technol. 2024 Feb;30(2):e13595. doi: 10.1111/srt.13595.
8
Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
J Invest Dermatol. 2023 Aug;143(8):1369-1377. doi: 10.1016/j.jid.2022.12.027. Epub 2023 Jun 15.
9
Characterization of health concerns in people with neurofibromatosis type 1.
Mol Genet Genomic Med. 2023 Jan;11(1):e2077. doi: 10.1002/mgg3.2077. Epub 2022 Nov 28.
10
Neurofibromatosis Clinical Trials-REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead.
Neurology. 2021 Aug 16;97(7 Supplement 1):S1-S3. doi: 10.1212/WNL.0000000000012429.

本文引用的文献

2
Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial.
J Invest Dermatol. 2019 May;139(5):1037-1044. doi: 10.1016/j.jid.2018.09.039. Epub 2018 Nov 24.
5
Simple method for estimating cutaneous neurofibromas in patients with neurofibromatosis 1.
J Dermatol. 2018 May;45(5):626-627. doi: 10.1111/1346-8138.14246.
6
Neurofibromatosis type 1.
Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X.
7
Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1.
J Dermatol. 2018 Jan;45(1):53-57. doi: 10.1111/1346-8138.14025. Epub 2017 Sep 11.
9
Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.
J Clin Oncol. 2016 Jun 10;34(17):1978-86. doi: 10.1200/JCO.2015.65.3576. Epub 2016 Feb 29.
10
The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.
J Genet Couns. 2015 Dec;24(6):931-44. doi: 10.1007/s10897-015-9829-5. Epub 2015 Apr 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验